A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

Inclusion Criteria:

   - Ability to understand and willingness to sign a written Informed Consent

   - Advanced relapsed or refractory predominantly non squamous NSCLC. The diagnosis must
   have been confirmed cyto-/ histologically

   - Patients must have measurable or non-measurable disease

   - At least two but not more than three prior standard treatment regimens for NSCLC

   - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

   - Male or female subjects >/= 18 years of age (>/=20 for Japan) at the time of Informed
   Consent

   - Life expectancy of at least 12 weeks

   - Ability to swallow oral medication

   - Both men and women using adequate barrier birth control measures during the course of
   the trial and 4 weeks after the completion of trial

   - Adequate bone marrow, liver and renal function as assessed by the following laboratory
   requirements to be conducted within 7 days prior to start of the study drug:

      - Haemoglobin > 9.0 g/dl

      - Absolute neutrophil count (ANC) >1,500/mm3

      - Platelet count >/= 100,000/µl

      - Total bilirubin
      - Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (      of normal in patients with liver metastases) Aspartate aminotransferase (AST) <
      2.5 x upper limit of normal (      metastases)

      - Alkaline phosphatase < 4 x upper limit of normal (      in patients with liver metastases)

      - Prothrombin Time (PT)-International Normalized Ratio (INR) or Partial
      Thromboplastin Time (PTT) < 1.5 x upper limit of normal

      - Serum creatinine < 1.5 x upper limit of normal

      - Calculated creatinine clearance of >/= 50 mL/min

Exclusion Criteria:

   - NSCLC patients with predominantly squamous cell carcinoma histology

Excluded medical conditions:

   - History of cardiac disease: Congestive heart failure, Active coronary artery disease
   (CAD), Cardiac arrhythmias (>Grade 2 NCI-CTCAE [National Cancer Institute-Common
   Terminology Criteria for Adverse Events] vers. 3.0)

   - Uncontrolled hypertension despite two anti-hypertensive medications

   - History of Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C

   - History of organ allograft

   - Active clinically serious infections (> grade 2 NCI-CTCAE vers. 3.0)

   - Patients with seizure disorder requiring medication

   - Patients with evidence or history of bleeding diathesis or coagulopathy

   - Patients undergoing renal dialysis

   - Pulmonary hemorrhage/ bleeding event >/= CTCAE grade 2 within four weeks prior to the
   first dose of the study drug

   - Any other hemorrhage/ bleeding event >/= CTCAE grade 3 within four weeks prior to the
   first dose of the study drug

   - Thrombotic or embolic venous or arterial events such as cerebrovascular accident

   - Pregnant or breast-feeding women.

   - Any condition which could affect the absorption or pharmacokinetics of the study drug

   - Prior treatment with other Vascular Endothelial Growth Factor (VEGF) (R) inhibitors,
   including compounds that impact vascularity (i.e. sunitinib, thalidomide, vandetanib,
   vascular disrupting agents [VDA], VEGF-trap and other experimental agents of this
   class). Only bevacizumab (Avastin) is permitted.